drugset
drugset / Trial / NCT03079869

Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients

NCT03079869 ↗

Phase 4 Completed 55 enrolled Kaiser Permanente Keryx Biopharmaceuticals · collab
NaSingle-groupOpen-labelSupportive care

Summary

Transition to Ferric Citrate among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 "Real World" Experience Study from Kaiser Permanente Southern California

Timeline

Start
2017-05-01
Primary completion
2019-09-14
Completion
2019-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric Citrate Unknown 1 g Oral

Indications

hyperphosphatemia